BRAF is altered in 4.6% of rectal carcinoma patients [2].

BRAF is an inclusion eligibility criterion in 1 clinical trial for rectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and rectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

KRAS is altered in 44.21% of rectal carcinoma patients [2].

KRAS is an inclusion eligibility criterion in 1 clinical trial for rectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and rectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NRAS is altered in 5.14% of rectal carcinoma patients [2].

NRAS is an inclusion eligibility criterion in 1 clinical trial for rectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and rectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3CA is altered in 13.12% of rectal carcinoma patients [2].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for rectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and rectal carcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].

PIK3R1 is altered in 3.18% of rectal carcinoma patients [2].

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for rectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and rectal carcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].

PTEN is altered in 3.71% of rectal carcinoma patients [2].

PTEN is an inclusion eligibility criterion in 1 clinical trial for rectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and rectal carcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].